Lihua Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lihua Zhang has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Boxuan Pu
National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
10 shared publicationsLubi Lei
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 102308, China
10 shared publications- Jing Li
National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
9 shared publications Yanwu Yu
National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
8 shared publicationsYue Peng
National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
8 shared publicationsJingkuo Li
National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China
7 shared publications
Latest Publications
- Open Access
- 22 July 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (22) , 2955-2962
Patient-reported health status vs. N-terminal pro-B-type natriuretic peptide levels in patients with acute heart failure
Background: Changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels may not fully translate into patient-reported health status in patients with heart failure (HF). We aimed to evaluate the correlation between NT-proBNP levels and patient-reported health status changes at one month after discharge of patients, and their associations with risk of death and rehospitalization in patients with acute HF. Methods: We used data from the China Patient-centered Evaluative Assessment of Cardiac Events Prospective Heart Failure Study (PEACE 5p-HF Study). Patient-reported health status was measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Patients who were hospitalized for HF and completed the KCCQ-12 and NT-proBNP tests before and one month after discharge were eligible in our study. We stratified patients into different groups based on NT-proBNP levels (i.e., improved, stable, and deteriorated) and KCCQ-12 scores (i.e., not deteriorated and deteriorated). We also examined the associations of the joint NT-proBNP and KCCQ-12 change with the risk of one-year and four-year clinical outcomes. Results: A total of 2461 patients were included in the analysis. The mean age was 64.06 ± 13.51 years, and 36.37% (895/2461) of the study population were female. Among patients with improved NT-proBNP levels, 115 (10.95%) patients had deteriorated KCCQ-12 scores. The correlation between the change in the KCCQ-12 score and NT-proBNP level was weak ( r 2 = 0.002, P = 0.013). Stratification by changes in the KCCQ-12 score revealed subgroups with distinctive risks, such that patients with deteriorated KCCQ-12 scores in any of the NT-proBNP change groups exhibited an increased risk of one-year all-cause death than participants with not deteriorated KCCQ-12 scores in any of the NT-proBNP change groups. Patients with improved NT-proBNP levels and deteriorated KCCQ-12 scores presented greater risks of one-year all-cause death (hazard ratio [HR]: 2.45, 95% confidence interval [CI]: 1.34–4.48) than patients with stable NT-proBNP levels and not deteriorated KCCQ-12 scores (HR [95% CI], 1.77 [1.25–2.53]). Conclusions: A discrepancy between changes in NT-proBNP levels and KCCQ-12 scores was common. The change in NT-proBNP levels was not sufficient to characterize critical aspects related to HF during one month after discharge of patients. Changes in the KCCQ-12 score exhibit complementary information to NT-proBNP levels for the prediction of clinical outcomes in patients with acute HF. Registration: www.clinicaltrials.gov (No. NCT02878811).
- 22 July 2025
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 138 (22) , 2955-2962
Open AccessPatient-reported health status vs. N-terminal pro-B-type natriuretic peptide levels in patients with acute heart failure
Background: Changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels may not fully translate into patient-reported health status in patients with heart failure (HF). We aimed to evaluate the correlation between NT-proBNP levels and patient-reported health status changes at one month after discharge of patients, and their associations with risk of death and rehospitalization in patients with acute HF. Methods: We used data from the China Patient-centered Evaluative Assessment of Cardiac Events Prospective Heart Failure Study (PEACE 5p-HF Study). Patient-reported health status was measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Patients who were hospitalized for HF and completed the KCCQ-12 and NT-proBNP tests before and one month after discharge were eligible in our study. We stratified patients into different groups based on NT-proBNP levels (i.e., improved, stable, and deteriorated) and KCCQ-12 scores (i.e., not deteriorated and deteriorated). We also examined the associations of the joint NT-proBNP and KCCQ-12 change with the risk of one-year and four-year clinical outcomes. Results: A total of 2461 patients were included in the analysis. The mean age was 64.06 ± 13.51 years, and 36.37% (895/2461) of the study population were female. Among patients with improved NT-proBNP levels, 115 (10.95%) patients had deteriorated KCCQ-12 scores. The correlation between the change in the KCCQ-12 score and NT-proBNP level was weak ( r 2 = 0.002, P = 0.013). Stratification by changes in the KCCQ-12 score revealed subgroups with distinctive risks, such that patients with deteriorated KCCQ-12 scores in any of the NT-proBNP change groups exhibited an increased risk of one-year all-cause death than participants with not deteriorated KCCQ-12 scores in any of the NT-proBNP change groups. Patients with improved NT-proBNP levels and deteriorated KCCQ-12 scores presented greater risks of one-year all-cause death (hazard ratio [HR]: 2.45, 95% confidence interval [CI]: 1.34–4.48) than patients with stable NT-proBNP levels and not deteriorated KCCQ-12 scores (HR [95% CI], 1.77 [1.25–2.53]). Conclusions: A discrepancy between changes in NT-proBNP levels and KCCQ-12 scores was common. The change in NT-proBNP levels was not sufficient to characterize critical aspects related to HF during one month after discharge of patients. Changes in the KCCQ-12 score exhibit complementary information to NT-proBNP levels for the prediction of clinical outcomes in patients with acute HF. Registration: www.clinicaltrials.gov (No. NCT02878811).
- Open Access
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002164
Occupational physical activity and risk of all-cause, cardiovascular disease and cancer mortality among adults in the USA: a national cohort study
Background: Evidence on the health effects of occupational physical activity (OPA) remains inconsistent, and potential sex-based differences in physical activity outcomes are understudied. Our goal was to investigate the relationships between OPA and leisure time physical activity (LTPA), both separately and in combination, and the risk of cancer, cardiovascular disease and all-cause mortality by sex. Methods: Using data from the NHANES 2007–2018 database, the study involved 29 404 adults aged 20 years and older with OPA. Physical activity was assessed through the Global Physical Activity Questionnaire, subjects were classified as inactive, insufficiently active, sufficiently active or highly active OPA. Mortality outcomes were determined by linking to the National Death Index records. Cox/Fine-Gray regressions were employed to investigate sex-specific multivariable-adjusted associations. Covariates including age, race, body mass index, smoking status, hypertension, diabetes mellitus, alcohol consumption, education, income to poverty ratio, marriage status, access to medical care, self-rated health, LTPA and history of diseases were adjusted in the multivariable models. Results: Over a median follow-up of 6.7 (3.7, 9.8) years for men and 6.8 (3.8,9.8) years for women, 1560 deaths in men and 1150 deaths in women occurred. For men, highly active OPA compared with inactivity was associated with 23% lower risk of all-cause mortality. For women, sufficiently active OPA compared with inactivity was associated with 36% lower risk of all-cause mortality. According to joint analyses that used inactive LTPA and inactive OPA as reference, ≥150 min LTPA was linked to the lowest risk of all-cause mortality (HR: 0.25; 95% CI 0.12 to 0.54) and cardiovascular mortality (HR 0.27, 95% CI 0.12 to 0.64) in women when combined with ≥150 min OPA. Conclusion: OPA had a beneficial association with cancer mortality in women and risk of all-cause mortality in both sexes. OPA and LTPA were jointly linked to a further decreased risk of death from all causes and cardiovascular disease in women.
- 1 July 2025
- Published by BMJ in BMJ Public Health
- Vol. 3 (2) , e002164
Open AccessOccupational physical activity and risk of all-cause, cardiovascular disease and cancer mortality among adults in the USA: a national cohort study
Background: Evidence on the health effects of occupational physical activity (OPA) remains inconsistent, and potential sex-based differences in physical activity outcomes are understudied. Our goal was to investigate the relationships between OPA and leisure time physical activity (LTPA), both separately and in combination, and the risk of cancer, cardiovascular disease and all-cause mortality by sex. Methods: Using data from the NHANES 2007–2018 database, the study involved 29 404 adults aged 20 years and older with OPA. Physical activity was assessed through the Global Physical Activity Questionnaire, subjects were classified as inactive, insufficiently active, sufficiently active or highly active OPA. Mortality outcomes were determined by linking to the National Death Index records. Cox/Fine-Gray regressions were employed to investigate sex-specific multivariable-adjusted associations. Covariates including age, race, body mass index, smoking status, hypertension, diabetes mellitus, alcohol consumption, education, income to poverty ratio, marriage status, access to medical care, self-rated health, LTPA and history of diseases were adjusted in the multivariable models. Results: Over a median follow-up of 6.7 (3.7, 9.8) years for men and 6.8 (3.8,9.8) years for women, 1560 deaths in men and 1150 deaths in women occurred. For men, highly active OPA compared with inactivity was associated with 23% lower risk of all-cause mortality. For women, sufficiently active OPA compared with inactivity was associated with 36% lower risk of all-cause mortality. According to joint analyses that used inactive LTPA and inactive OPA as reference, ≥150 min LTPA was linked to the lowest risk of all-cause mortality (HR: 0.25; 95% CI 0.12 to 0.54) and cardiovascular mortality (HR 0.27, 95% CI 0.12 to 0.64) in women when combined with ≥150 min OPA. Conclusion: OPA had a beneficial association with cancer mortality in women and risk of all-cause mortality in both sexes. OPA and LTPA were jointly linked to a further decreased risk of death from all causes and cardiovascular disease in women.
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (7) , e039350
Rationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve Replacement
Background: Current guidelines and expert consensus recommend lifelong single antiplatelet therapy for patients undergoing transcatheter aortic valve replacement who have no indication for anticoagulation or dual antiplatelet therapy. However, there is no direct evidence from randomized controlled trials supporting this practice. Furthermore, the optimal duration of antiplatelet therapy in this population has not been adequately investigated. Methods and Results: CREATE (A Multicenter Randomized Controlled Study to Evaluate Cessation of Antithrombotic Therapy at 1 Year in TAVR Patients–The CREATE Study) is a prospective, multicenter, open‐label, randomized controlled trial for patients who have undergone successful transcatheter aortic valve replacement and have no indication for long‐term oral anticoagulation or antiplatelet therapy. Eligible patients are free from major bleeding and ischemic events for 1 year postprocedure before being randomized 1:1 to single antiplatelet therapy (control group) or no antiplatelet therapy (experimental group). The primary efficacy end point is the incidence of bleeding events, defined by the VARC‐3 (Valve Academic Research Consortium‐3) criteria, at 1‐year postrandomization. The primary safety end point is a composite of cardiac death, myocardial infarction, and ischemic stroke at 1 year. The trial is powered for both superiority in efficiency and noninferiority in safety. Accordingly, a total of 3380 patients will be enrolled. Conclusions: The CREATE trial aims to assess if stopping antiplatelet therapy at 1‐year after transcatheter aortic valve replacement reduces bleeding risk without increasing ischemic events in patients not requiring chronic antithrombotic therapy. Registration: URL: https://www.chictr.org.cn ; Unique identifier: ChiCTR2400087454.
- 1 April 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (7) , e039350
Open AccessRationale and Design of the CREATE Trial: A Multicenter, Randomized Comparison of Continuation or Cessation of Single Antithrombotic Therapy at 1 Year After Transcatheter Aortic Valve Replacement
Background: Current guidelines and expert consensus recommend lifelong single antiplatelet therapy for patients undergoing transcatheter aortic valve replacement who have no indication for anticoagulation or dual antiplatelet therapy. However, there is no direct evidence from randomized controlled trials supporting this practice. Furthermore, the optimal duration of antiplatelet therapy in this population has not been adequately investigated. Methods and Results: CREATE (A Multicenter Randomized Controlled Study to Evaluate Cessation of Antithrombotic Therapy at 1 Year in TAVR Patients–The CREATE Study) is a prospective, multicenter, open‐label, randomized controlled trial for patients who have undergone successful transcatheter aortic valve replacement and have no indication for long‐term oral anticoagulation or antiplatelet therapy. Eligible patients are free from major bleeding and ischemic events for 1 year postprocedure before being randomized 1:1 to single antiplatelet therapy (control group) or no antiplatelet therapy (experimental group). The primary efficacy end point is the incidence of bleeding events, defined by the VARC‐3 (Valve Academic Research Consortium‐3) criteria, at 1‐year postrandomization. The primary safety end point is a composite of cardiac death, myocardial infarction, and ischemic stroke at 1 year. The trial is powered for both superiority in efficiency and noninferiority in safety. Accordingly, a total of 3380 patients will be enrolled. Conclusions: The CREATE trial aims to assess if stopping antiplatelet therapy at 1‐year after transcatheter aortic valve replacement reduces bleeding risk without increasing ischemic events in patients not requiring chronic antithrombotic therapy. Registration: URL: https://www.chictr.org.cn ; Unique identifier: ChiCTR2400087454.
- 4 January 2025
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 189, 112032
Association of depressive symptoms and cardiovascular health with mortality among U.S. adults
- 4 January 2025
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 189, 112032
Association of depressive symptoms and cardiovascular health with mortality among U.S. adults
- Open Access
- 1 January 2025
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 15 (1) , 484-495
Associations of Cardiovascular-Kidney-Metabolic Syndrome with Premature Mortality and Life Expectancies in US Adults: A Cohort Study
Background: The American Heart Association has recently updated the Cardiovascular-Kidney-Metabolic (CKM) Health Advisory, proposing a new framework for defining, staging, and predicting CKM risk. However, the prevalence and adverse effects of the CKM stages remain insufficiently characterized. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (1999–2018), including 18,350 US adults aged 20–79 years. CKM syndrome encompasses subclinical or clinical cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic risk factors. The participants were categorized into 4 CKM stages based on their clinical severity. We assessed associations of CKM stages with mortality risk and life expectancy. Results: Only 12.9% of participants were classified as having CKM stage 0. The prevalence of CKM stages 1, 2, 3, and 4 was 23.1%, 53.6%, 3.6%, and 6.7%, respectively. Compared with CKM stage 0, individuals in stage 4 had a markedly higher risk of all-cause mortality (HR: 4.30, 95% CI: 2.95–6.26) and lost 15.5 (12.5–19.8) years of life at age 50 years. Sex and racial/ethnic disparities were also observed. Conclusions: A higher CKM stage was strongly associated with increased mortality and reduced life expectancy. Our findings underscore the urgent need for enhanced CKM health management, social support, and policy intervention.
- 1 January 2025
- Published by S. Karger AG in Cardiorenal Medicine
- Vol. 15 (1) , 484-495
Open AccessAssociations of Cardiovascular-Kidney-Metabolic Syndrome with Premature Mortality and Life Expectancies in US Adults: A Cohort Study
Background: The American Heart Association has recently updated the Cardiovascular-Kidney-Metabolic (CKM) Health Advisory, proposing a new framework for defining, staging, and predicting CKM risk. However, the prevalence and adverse effects of the CKM stages remain insufficiently characterized. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (1999–2018), including 18,350 US adults aged 20–79 years. CKM syndrome encompasses subclinical or clinical cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic risk factors. The participants were categorized into 4 CKM stages based on their clinical severity. We assessed associations of CKM stages with mortality risk and life expectancy. Results: Only 12.9% of participants were classified as having CKM stage 0. The prevalence of CKM stages 1, 2, 3, and 4 was 23.1%, 53.6%, 3.6%, and 6.7%, respectively. Compared with CKM stage 0, individuals in stage 4 had a markedly higher risk of all-cause mortality (HR: 4.30, 95% CI: 2.95–6.26) and lost 15.5 (12.5–19.8) years of life at age 50 years. Sex and racial/ethnic disparities were also observed. Conclusions: A higher CKM stage was strongly associated with increased mortality and reduced life expectancy. Our findings underscore the urgent need for enhanced CKM health management, social support, and policy intervention.
- Open Access
Associations of Cardiovascular-Kidney-Metabolic syndrome with premature mortality and life expectancies in US adults: a cohort study
Background: The American Heart Association recently updated the Cardiovascular-Kidney-Metabolic (CKM) Health advisory, proposing a new framework for defining, staging, and predicting CKM risk. However, the prevalence and adverse effects of CKM stages remain insufficiently characterized. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (1999–2018), including 18,350 US adults aged 20– 79 years. CKM syndrome encompasses subclinical or clinical cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic risk factors. Participants were categorized into four CKM stages based on clinical severity. We assessed associations of CKM stages with mortality risk and life expectancy. Results: Only 12.9% of participants were classified as CKM stage 0. The prevalence of CKM stages 1, 2, 3, and 4 was 23.1%, 53.6%, 3.6%, and 6.7%, respectively. Compared to CKM stage 0, individuals in stage 4 had a markedly higher risk of all-cause mortality (HR: 4.30, 95% CI: 2.95– 6.26) and lost 15.5 (12.5–19.8) years of life at age 50. Sex and racial/ethnic disparities were also observed. Conclusions: Higher CKM stages were strongly associated with increased mortality and reduced life expectancy. Our findings underscore the urgent need for enhanced CKM health management, social support, and policy interventions. Key Messages: What is already known on this topic: Metabolic disorders, chronic kidney disease, and cardiovascular diseases are significantly associated with premature mortality. By taking into account the overlaps between cardiovascular-kidney-metabolic (CKM) syndrome, it is possible to improve risk stratification and employ an integrated approach to multimorbidity management. What this study adds?: Only 12.6% of individuals had no CKM conditions, whereas approximately 50% of individuals had CKM stage 2, encompassing metabolic disorders, chronic kidney disease, or a combination of both. The estimated life expectancy of individuals with CKM stage 4 was 15.5 years lower than that of individuals with CKM stage 0 at the age of 50. How this study might affect research, practice or policy?: Our results indicate that the CKM condition is prevalent among US adults. We advocate the implementation of the new staging system for the prevention and treatment of CKM syndrome. Life expectancy is reduced in adults who have a combination of metabolic risk factors, chronic kidney disease, or cardiovascular disease. We highlight the importance of incorporating a people-centered approach that includes the development of social support and policy, the integration of CKM health multidisciplinary management, and the enhancement of obesity management.
Open AccessAssociations of Cardiovascular-Kidney-Metabolic syndrome with premature mortality and life expectancies in US adults: a cohort study
Background: The American Heart Association recently updated the Cardiovascular-Kidney-Metabolic (CKM) Health advisory, proposing a new framework for defining, staging, and predicting CKM risk. However, the prevalence and adverse effects of CKM stages remain insufficiently characterized. Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) (1999–2018), including 18,350 US adults aged 20– 79 years. CKM syndrome encompasses subclinical or clinical cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic risk factors. Participants were categorized into four CKM stages based on clinical severity. We assessed associations of CKM stages with mortality risk and life expectancy. Results: Only 12.9% of participants were classified as CKM stage 0. The prevalence of CKM stages 1, 2, 3, and 4 was 23.1%, 53.6%, 3.6%, and 6.7%, respectively. Compared to CKM stage 0, individuals in stage 4 had a markedly higher risk of all-cause mortality (HR: 4.30, 95% CI: 2.95– 6.26) and lost 15.5 (12.5–19.8) years of life at age 50. Sex and racial/ethnic disparities were also observed. Conclusions: Higher CKM stages were strongly associated with increased mortality and reduced life expectancy. Our findings underscore the urgent need for enhanced CKM health management, social support, and policy interventions. Key Messages: What is already known on this topic: Metabolic disorders, chronic kidney disease, and cardiovascular diseases are significantly associated with premature mortality. By taking into account the overlaps between cardiovascular-kidney-metabolic (CKM) syndrome, it is possible to improve risk stratification and employ an integrated approach to multimorbidity management. What this study adds?: Only 12.6% of individuals had no CKM conditions, whereas approximately 50% of individuals had CKM stage 2, encompassing metabolic disorders, chronic kidney disease, or a combination of both. The estimated life expectancy of individuals with CKM stage 4 was 15.5 years lower than that of individuals with CKM stage 0 at the age of 50. How this study might affect research, practice or policy?: Our results indicate that the CKM condition is prevalent among US adults. We advocate the implementation of the new staging system for the prevention and treatment of CKM syndrome. Life expectancy is reduced in adults who have a combination of metabolic risk factors, chronic kidney disease, or cardiovascular disease. We highlight the importance of incorporating a people-centered approach that includes the development of social support and policy, the integration of CKM health multidisciplinary management, and the enhancement of obesity management.
- Top Cited PapersOpen Access
- 20 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (16) , e034996
Social Risk Profile and Cardiovascular‐Kidney‐Metabolic Syndrome in US Adults
Background: Poor cardiovascular‐kidney‐metabolic (CKM) health is associated with premature mortality and excess morbidity in the United States. Adverse social conditions have a prominent impact on cardiometabolic diseases during the life course. We aim to examine the association between social risk profile (SRP) and CKM multimorbidity among US adults. Methods and Results: We used data from the National Health and Nutrition Examination Survey from 1999 to 2018. The definition of CKM syndrome is the coexistence of subclinical or clinical cardiovascular disease, chronic kidney disease, and metabolic disorders. We classified participants by 4 CKM stages according to the different clinical severity of different forms of CKM syndrome. We calculated the summed number of positive SRP measures, including employed, high‐income level, food secure, high education attainment, private insurance, owning a house, and married, as SRP scores and classified them into 4 levels by quartiles: low (0–2), lower‐middle (3–4), upper‐middle (5–6), and high (7–8). A total of 18 373 US adults, aged 20 to 79 years, were included in our analyses. There were 2567 (9.4%) participants with low SRP score level. Most individual SRP measures and a combined SRP score were associated with CKM stages. Compared with high SRP score level, low SRP level was associated with higher odds of having CKM stage 1 (odds ratio [OR], 1.34 [95% CI, 1.06–1.70]), CKM stage 2 (OR, 2.03 [95% CI, 1.59–2.58]), CKM stage 3 (OR, 5.28 [95% CI, 3.29–8.47]), and CKM stage 4 (OR, 5.97 [95% CI, 4.20–8.49]). Conclusions: Cumulative social disadvantage, denoted by higher SRP burden, was associated with higher odds of CKM multimorbidity, independent of demographic and lifestyle factors.
- 20 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (16) , e034996
Top Cited PapersOpen AccessSocial Risk Profile and Cardiovascular‐Kidney‐Metabolic Syndrome in US Adults
Background: Poor cardiovascular‐kidney‐metabolic (CKM) health is associated with premature mortality and excess morbidity in the United States. Adverse social conditions have a prominent impact on cardiometabolic diseases during the life course. We aim to examine the association between social risk profile (SRP) and CKM multimorbidity among US adults. Methods and Results: We used data from the National Health and Nutrition Examination Survey from 1999 to 2018. The definition of CKM syndrome is the coexistence of subclinical or clinical cardiovascular disease, chronic kidney disease, and metabolic disorders. We classified participants by 4 CKM stages according to the different clinical severity of different forms of CKM syndrome. We calculated the summed number of positive SRP measures, including employed, high‐income level, food secure, high education attainment, private insurance, owning a house, and married, as SRP scores and classified them into 4 levels by quartiles: low (0–2), lower‐middle (3–4), upper‐middle (5–6), and high (7–8). A total of 18 373 US adults, aged 20 to 79 years, were included in our analyses. There were 2567 (9.4%) participants with low SRP score level. Most individual SRP measures and a combined SRP score were associated with CKM stages. Compared with high SRP score level, low SRP level was associated with higher odds of having CKM stage 1 (odds ratio [OR], 1.34 [95% CI, 1.06–1.70]), CKM stage 2 (OR, 2.03 [95% CI, 1.59–2.58]), CKM stage 3 (OR, 5.28 [95% CI, 3.29–8.47]), and CKM stage 4 (OR, 5.97 [95% CI, 4.20–8.49]). Conclusions: Cumulative social disadvantage, denoted by higher SRP burden, was associated with higher odds of CKM multimorbidity, independent of demographic and lifestyle factors.
- Open Access
- 8 August 2024
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (8) , 279
Characteristics and Factors of 30-Day Readmissions after Hospitalization for Acute Heart Failure in China
Background: Patients with acute heart failure (HF) are at high risk of 30-day readmission. Little is known about the characteristics and associated factors of 30-day readmissions among patients with acute HF in China. Methods: We enrolled consecutive patients hospitalized for acute HF and discharged from 52 hospitals in China from August 2016 to May 2018. We describe the rate of 30-day readmission, the time interval from discharge to readmission, and the causes of readmission. We also analyzed the factors associated with readmission risk by fitting multivariate Cox proportional hazards models. Results: We included 4875 patients with a median age of 67 years (interquartile range, 57–75), 3045 (62.5%) of whom were male. Within 30 days after discharge, 613 (12.6%) patients were readmitted for all causes, with a median from discharge to readmission of 12 (6–21) days. Most readmissions were attributed to cardiovascular causes (71.1%) and 60.0% to HF-related causes. Readmission occurred within 14 days of discharge in more than half of the patients (56.4%). Diabetes (hazard ratio [HR]: 1.25, 95% confidence interval [95% CI]: 1.06–1.50), anemia (HR: 1.26, 95% CI: 1.03–1.53), high New York Heart Association classification (HR: 1.48, 95% CI: 1.08–2.01), elevated N-terminal pro-B type natriuretic peptide (HR: 1.67, 95% CI: 1.24–2.25), and high-sensitivity cardiac troponin T (HR: 1.26, 95% CI: 1.01–1.58) were associated with increased risks of readmission. High systolic blood pressure (HR: 0.56, 95% CI: 0.38–0.81) and Kansas City Cardiomyopathy Questionnaire-12 scores (HR: 0.64, 95% CI: 0.44–0.94) were associated with decreased risk of readmission. Conclusions: In China, almost one in eight patients with acute HF were readmitted within 30 days after discharge, mainly due to cardiovascular reasons, and approximately three-fifths of the readmissions occurred in the first 14 days. Both clinical and patient-centered characteristics were associated with readmission.
- 8 August 2024
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 25 (8) , 279
Open AccessCharacteristics and Factors of 30-Day Readmissions after Hospitalization for Acute Heart Failure in China
Background: Patients with acute heart failure (HF) are at high risk of 30-day readmission. Little is known about the characteristics and associated factors of 30-day readmissions among patients with acute HF in China. Methods: We enrolled consecutive patients hospitalized for acute HF and discharged from 52 hospitals in China from August 2016 to May 2018. We describe the rate of 30-day readmission, the time interval from discharge to readmission, and the causes of readmission. We also analyzed the factors associated with readmission risk by fitting multivariate Cox proportional hazards models. Results: We included 4875 patients with a median age of 67 years (interquartile range, 57–75), 3045 (62.5%) of whom were male. Within 30 days after discharge, 613 (12.6%) patients were readmitted for all causes, with a median from discharge to readmission of 12 (6–21) days. Most readmissions were attributed to cardiovascular causes (71.1%) and 60.0% to HF-related causes. Readmission occurred within 14 days of discharge in more than half of the patients (56.4%). Diabetes (hazard ratio [HR]: 1.25, 95% confidence interval [95% CI]: 1.06–1.50), anemia (HR: 1.26, 95% CI: 1.03–1.53), high New York Heart Association classification (HR: 1.48, 95% CI: 1.08–2.01), elevated N-terminal pro-B type natriuretic peptide (HR: 1.67, 95% CI: 1.24–2.25), and high-sensitivity cardiac troponin T (HR: 1.26, 95% CI: 1.01–1.58) were associated with increased risks of readmission. High systolic blood pressure (HR: 0.56, 95% CI: 0.38–0.81) and Kansas City Cardiomyopathy Questionnaire-12 scores (HR: 0.64, 95% CI: 0.44–0.94) were associated with decreased risk of readmission. Conclusions: In China, almost one in eight patients with acute HF were readmitted within 30 days after discharge, mainly due to cardiovascular reasons, and approximately three-fifths of the readmissions occurred in the first 14 days. Both clinical and patient-centered characteristics were associated with readmission.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (6) , e011118
Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction
BACKGROUND: Heart failure with preserved ejection fraction is a major global public health problem, while effective risk stratification tools are still lacking. We sought to construct a multi-mRNA signature to predict 1-year all-cause death. METHODS: We selected 30 patients with heart failure with preserved ejection fraction who died during 1-year follow-up and 30 who survived in the discovery set. One hundred seventy-one and 120 patients with heart failure with preserved ejection fraction were randomly selected as a test set and a validation set, respectively. We performed mRNA microarrays in all patients. RESULTS: We constructed a 5-mRNA signature for predicting 1-year all-cause death. The scores of the 5-mRNA signature were significantly associated with the 1-year risk of all-cause death in both the test set (hazard ratio, 2.72 [95% CI, 1.98–3.74]; P P P <0.001). CONCLUSIONS: The 5-mRNA signature is a promising predictive tool for 1-year all-cause death and shows improved prognostic power over the established risk scores and NT-proBNP in patients with heart failure with preserved ejection fraction.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (6) , e011118
Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction
BACKGROUND: Heart failure with preserved ejection fraction is a major global public health problem, while effective risk stratification tools are still lacking. We sought to construct a multi-mRNA signature to predict 1-year all-cause death. METHODS: We selected 30 patients with heart failure with preserved ejection fraction who died during 1-year follow-up and 30 who survived in the discovery set. One hundred seventy-one and 120 patients with heart failure with preserved ejection fraction were randomly selected as a test set and a validation set, respectively. We performed mRNA microarrays in all patients. RESULTS: We constructed a 5-mRNA signature for predicting 1-year all-cause death. The scores of the 5-mRNA signature were significantly associated with the 1-year risk of all-cause death in both the test set (hazard ratio, 2.72 [95% CI, 1.98–3.74]; P P P <0.001). CONCLUSIONS: The 5-mRNA signature is a promising predictive tool for 1-year all-cause death and shows improved prognostic power over the established risk scores and NT-proBNP in patients with heart failure with preserved ejection fraction.
- 6 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (1) , 68-77
Association of cumulative health status with subsequent mortality in patients with acute heart failure
We aim to examine the association between long-term cumulative health status and subsequent mortality among patients with acute heart failure (HF). Based on a national prospective cohort study of patients hospitalized for HF, we measured health status by Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 at 4 time points, i.e. admission, 1-,6- and 12-month after discharge. Cumulative health status was interpreted by cumulative KCCQ-12 score and cumulative times of good health status. Outcomes included subsequent all-cause and cardiovascular mortality. Multivariable Cox proportional hazard models were performed to examine the association between cumulative health status and subsequent mortality. Totally, 2328 patients (36.7% women and median age 66 [IQR: 56–75] years) were included, the median follow-up was 4.34 (IQR: 3.93–4.96) years. Compared with Quartile 4, the lowest Quartile 1 had the highest HR for all-cause mortality (2.96; 95% CI: 2.26–3.87), followed by Quartile 2 (1.79; 95% CI: 1.37–2.34) and Quartile 3 (1.62; 95% CI: 1.23–2.12). Patients with 0-time of good health status had the highest risk of all-cause mortality (HR: 2.41, 95% CI: 1.69–3.46) compared with patients with 4-times of good health status. Similar associations persisted for cardiovascular mortality. A greater burden of cumulative health status indicated worse survival among patients hospitalized for HF. Repeated KCCQ measurements could be helpful to monitor long-term health status and identify patients vulnerable to death. Clinical Trial Registration: www.clinicaltrials.gov (NCT02878811)
- 6 March 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (1) , 68-77
Association of cumulative health status with subsequent mortality in patients with acute heart failure
We aim to examine the association between long-term cumulative health status and subsequent mortality among patients with acute heart failure (HF). Based on a national prospective cohort study of patients hospitalized for HF, we measured health status by Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 at 4 time points, i.e. admission, 1-,6- and 12-month after discharge. Cumulative health status was interpreted by cumulative KCCQ-12 score and cumulative times of good health status. Outcomes included subsequent all-cause and cardiovascular mortality. Multivariable Cox proportional hazard models were performed to examine the association between cumulative health status and subsequent mortality. Totally, 2328 patients (36.7% women and median age 66 [IQR: 56–75] years) were included, the median follow-up was 4.34 (IQR: 3.93–4.96) years. Compared with Quartile 4, the lowest Quartile 1 had the highest HR for all-cause mortality (2.96; 95% CI: 2.26–3.87), followed by Quartile 2 (1.79; 95% CI: 1.37–2.34) and Quartile 3 (1.62; 95% CI: 1.23–2.12). Patients with 0-time of good health status had the highest risk of all-cause mortality (HR: 2.41, 95% CI: 1.69–3.46) compared with patients with 4-times of good health status. Similar associations persisted for cardiovascular mortality. A greater burden of cumulative health status indicated worse survival among patients hospitalized for HF. Repeated KCCQ measurements could be helpful to monitor long-term health status and identify patients vulnerable to death. Clinical Trial Registration: www.clinicaltrials.gov (NCT02878811)